Double-Barreled drug attack targets Hard-to-Treat breast cancer
NCT ID NCT07701941
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This trial is studying a combination of two targeted drugs, patritumab deruxtecan and trastuzumab deruxtecan, for people with a specific type of advanced breast cancer that is hormone receptor positive and has low or ultra-low levels of a protein called HER2. The study aims to find the best dose and see how safe and effective the combination is at shrinking tumors. Participants have cancer that has spread or cannot be removed by surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of two antibody-drug conjugates: patritumab deruxtecan (HER3-DXd) and trastuzumab deruxtecan (T-DXd)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced breast cancer that has limited HER2 expression.
- What could go wrong
- This is an early-phase trial, so the combination may not prove effective or safe enough for wider use. Side effects from these powerful drugs can be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-LOW OR HER2-ULTRALOW are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.